schliessen

Filtern

 

Bibliotheken

Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events

We investigated in a longitudinal, multicenter, cohort study whether combined lipid apheresis and lipid-lowering medication can reduce extremely high levels of lipoprotein(a) (Lp[a]) and thus prevent major adverse coronary events (MACE) more efficaciously than lipid-lowering medication alone. Eligib... Full description

Journal Title: Nature clinical practice cardiovascular medicine 2009-03, Vol.6 (3), p.229-239
Main Author: Jaeger, Beate R
Other Authors: Richter, Yvonne , Nagel, Dorothea , Heigl, Franz , Vogt, Anja , Roeseler, Eberhard , Parhofer, Klaus , Ramlow, Wolfgang , Koch, Michael , Utermann, Gerd , Labarrere, Carlos A , Seidel, Dietrich
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: England: Nature Publishing Group
ID: ISSN: 1743-4297
Link: https://www.ncbi.nlm.nih.gov/pubmed/19234501
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_66953323
title: Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events
format: Article
creator:
  • Jaeger, Beate R
  • Richter, Yvonne
  • Nagel, Dorothea
  • Heigl, Franz
  • Vogt, Anja
  • Roeseler, Eberhard
  • Parhofer, Klaus
  • Ramlow, Wolfgang
  • Koch, Michael
  • Utermann, Gerd
  • Labarrere, Carlos A
  • Seidel, Dietrich
subjects:
  • Adult
  • Aged
  • Antilipemic agents
  • Blood Component Removal
  • Blood lipoproteins
  • Cohort Studies
  • Combined Modality Therapy
  • Coronary Artery Disease - drug therapy
  • Coronary Artery Disease - prevention & control
  • Coronary Artery Disease - therapy
  • Coronary heart disease
  • Dosage and administration
  • Female
  • Health aspects
  • Humans
  • Hypolipidemic Agents - therapeutic use
  • Lipoprotein(a) - blood
  • Lipoproteins
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Prevention
  • Proteolipids
  • Risk factors
  • Treatment Outcome
ispartof: Nature clinical practice cardiovascular medicine, 2009-03, Vol.6 (3), p.229-239
description: We investigated in a longitudinal, multicenter, cohort study whether combined lipid apheresis and lipid-lowering medication can reduce extremely high levels of lipoprotein(a) (Lp[a]) and thus prevent major adverse coronary events (MACE) more efficaciously than lipid-lowering medication alone. Eligible patients had coronary artery disease and Lp(a) levels > or =2.14 micromol/l (95th percentile). All patients received lipid-lowering medications alone until maximally tolerated doses were no longer effective, followed by combined lipid apheresis and lipid-lowering medication. The rates of the primary outcome, MACE, were recorded for both periods. A total of 120 patients were included. The mean duration of lipid-lowering therapy alone was 5.6+/-5.8 years, and that of apheresis was 5.0+/-3.6 years. Median Lp(a) concentration was reduced from 4.00 micromol/l to 1.07 micromol/l with apheresis treatment (P
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 1743-4297
fulltext: fulltext
issn:
  • 1743-4297
  • 1759-5002
  • 1743-4300
  • 1759-5010
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.6191201
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_66953323
sourceformatXML
sourcesystemPC
galeidA194904953
sourcerecordidA194904953
originalsourceidFETCH-LOGICAL-c405t-5a4d5123282608581f831cf8190ad67e3ec6250d98ac32aedf7c042b65452f173
addsrcrecordideNp1ks9vFCEUx4nR2Lp69GpITEw9bOXnMHNsGqsmm3jR84TCY4fNDIzAbNJ_xb9W1q4222g48IDP98vj8RB6TcklJbz9EMxsdLI-UiGbJ-icKsHXghPy9E_MOnWGXuS8I4Qrxdvn6Ix2jAtJ6Dn6uYlh68tifdAjNnGIqeBc13c4BlwGwOAcmOL3ECBnHB0e_ewt1vMACbLPuCTQZYJQcIk4gV0M4MFvhwMY5xQL-HCh3-MR9jBmrIPFc6pxFUx6FxPWdg8pQ709xaDTHf59mF-iZ06PGV4d5xX6fvPx2_Xn9ebrpy_XV5u1EUSWtdTCSso4a1lDWtlS13JqXEs7om2jgINpmCS2a7XhTIN1yhDBbhspJHNU8RV6d-9bc_2xQC795LOBcdQB4pL7pukk54xX8O0jcBeXVOuWe6raljGmFH2gtnqE3gcXS9LmYNlf0U50RBzsVujyH1QdFiZvYgDn6_6JYH0vMCnmnMD1c_JTrVZPSX_ohP6kEyr_5pjscjuBfaCPX18B_sjQ-KKLj6Fm4sf_2h5fF3RZEvy1PaV-ARvs0MM
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid1788222771
display
typearticle
titleLongitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events
sourceAlma/SFX Local Collection
creatorJaeger, Beate R ; Richter, Yvonne ; Nagel, Dorothea ; Heigl, Franz ; Vogt, Anja ; Roeseler, Eberhard ; Parhofer, Klaus ; Ramlow, Wolfgang ; Koch, Michael ; Utermann, Gerd ; Labarrere, Carlos A ; Seidel, Dietrich
creatorcontribJaeger, Beate R ; Richter, Yvonne ; Nagel, Dorothea ; Heigl, Franz ; Vogt, Anja ; Roeseler, Eberhard ; Parhofer, Klaus ; Ramlow, Wolfgang ; Koch, Michael ; Utermann, Gerd ; Labarrere, Carlos A ; Seidel, Dietrich ; Group of Clinical Investigators ; for the Group of Clinical Investigators
descriptionWe investigated in a longitudinal, multicenter, cohort study whether combined lipid apheresis and lipid-lowering medication can reduce extremely high levels of lipoprotein(a) (Lp[a]) and thus prevent major adverse coronary events (MACE) more efficaciously than lipid-lowering medication alone. Eligible patients had coronary artery disease and Lp(a) levels > or =2.14 micromol/l (95th percentile). All patients received lipid-lowering medications alone until maximally tolerated doses were no longer effective, followed by combined lipid apheresis and lipid-lowering medication. The rates of the primary outcome, MACE, were recorded for both periods. A total of 120 patients were included. The mean duration of lipid-lowering therapy alone was 5.6+/-5.8 years, and that of apheresis was 5.0+/-3.6 years. Median Lp(a) concentration was reduced from 4.00 micromol/l to 1.07 micromol/l with apheresis treatment (P<0.0001); the corresponding mean annual MACE rate per patient was 1.056 versus 0.144 (P<0.0001). Lowering of Lp(a) levels by apheresis was efficacious and safe, and we recommend this therapy for patients in whom maximally tolerated doses of medication alone have failed to control coronary artery disease-associated events.
identifier
0ISSN: 1743-4297
1ISSN: 1759-5002
2EISSN: 1743-4300
3EISSN: 1759-5010
4DOI: 10.1038/ncpcardio1456
5PMID: 19234501
languageeng
publisherEngland: Nature Publishing Group
subjectAdult ; Aged ; Antilipemic agents ; Blood Component Removal ; Blood lipoproteins ; Cohort Studies ; Combined Modality Therapy ; Coronary Artery Disease - drug therapy ; Coronary Artery Disease - prevention & control ; Coronary Artery Disease - therapy ; Coronary heart disease ; Dosage and administration ; Female ; Health aspects ; Humans ; Hypolipidemic Agents - therapeutic use ; Lipoprotein(a) - blood ; Lipoproteins ; Longitudinal Studies ; Male ; Middle Aged ; Prevention ; Proteolipids ; Risk factors ; Treatment Outcome
ispartofNature clinical practice cardiovascular medicine, 2009-03, Vol.6 (3), p.229-239
rights
0COPYRIGHT 2009 Nature Publishing Group
1Copyright Nature Publishing Group Mar 2009
lds50peer_reviewed
citedbyFETCH-LOGICAL-c405t-5a4d5123282608581f831cf8190ad67e3ec6250d98ac32aedf7c042b65452f173
citesFETCH-LOGICAL-c405t-5a4d5123282608581f831cf8190ad67e3ec6250d98ac32aedf7c042b65452f173
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19234501$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Jaeger, Beate R
1Richter, Yvonne
2Nagel, Dorothea
3Heigl, Franz
4Vogt, Anja
5Roeseler, Eberhard
6Parhofer, Klaus
7Ramlow, Wolfgang
8Koch, Michael
9Utermann, Gerd
10Labarrere, Carlos A
11Seidel, Dietrich
12Group of Clinical Investigators
13for the Group of Clinical Investigators
title
0Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events
1Nature clinical practice cardiovascular medicine
addtitleNat Clin Pract Cardiovasc Med
descriptionWe investigated in a longitudinal, multicenter, cohort study whether combined lipid apheresis and lipid-lowering medication can reduce extremely high levels of lipoprotein(a) (Lp[a]) and thus prevent major adverse coronary events (MACE) more efficaciously than lipid-lowering medication alone. Eligible patients had coronary artery disease and Lp(a) levels > or =2.14 micromol/l (95th percentile). All patients received lipid-lowering medications alone until maximally tolerated doses were no longer effective, followed by combined lipid apheresis and lipid-lowering medication. The rates of the primary outcome, MACE, were recorded for both periods. A total of 120 patients were included. The mean duration of lipid-lowering therapy alone was 5.6+/-5.8 years, and that of apheresis was 5.0+/-3.6 years. Median Lp(a) concentration was reduced from 4.00 micromol/l to 1.07 micromol/l with apheresis treatment (P<0.0001); the corresponding mean annual MACE rate per patient was 1.056 versus 0.144 (P<0.0001). Lowering of Lp(a) levels by apheresis was efficacious and safe, and we recommend this therapy for patients in whom maximally tolerated doses of medication alone have failed to control coronary artery disease-associated events.
subject
0Adult
1Aged
2Antilipemic agents
3Blood Component Removal
4Blood lipoproteins
5Cohort Studies
6Combined Modality Therapy
7Coronary Artery Disease - drug therapy
8Coronary Artery Disease - prevention & control
9Coronary Artery Disease - therapy
10Coronary heart disease
11Dosage and administration
12Female
13Health aspects
14Humans
15Hypolipidemic Agents - therapeutic use
16Lipoprotein(a) - blood
17Lipoproteins
18Longitudinal Studies
19Male
20Middle Aged
21Prevention
22Proteolipids
23Risk factors
24Treatment Outcome
issn
01743-4297
11759-5002
21743-4300
31759-5010
fulltexttrue
rsrctypearticle
creationdate2009
recordtypearticle
recordideNp1ks9vFCEUx4nR2Lp69GpITEw9bOXnMHNsGqsmm3jR84TCY4fNDIzAbNJ_xb9W1q4222g48IDP98vj8RB6TcklJbz9EMxsdLI-UiGbJ-icKsHXghPy9E_MOnWGXuS8I4Qrxdvn6Ix2jAtJ6Dn6uYlh68tifdAjNnGIqeBc13c4BlwGwOAcmOL3ECBnHB0e_ewt1vMACbLPuCTQZYJQcIk4gV0M4MFvhwMY5xQL-HCh3-MR9jBmrIPFc6pxFUx6FxPWdg8pQ709xaDTHf59mF-iZ06PGV4d5xX6fvPx2_Xn9ebrpy_XV5u1EUSWtdTCSso4a1lDWtlS13JqXEs7om2jgINpmCS2a7XhTIN1yhDBbhspJHNU8RV6d-9bc_2xQC795LOBcdQB4pL7pukk54xX8O0jcBeXVOuWe6raljGmFH2gtnqE3gcXS9LmYNlf0U50RBzsVujyH1QdFiZvYgDn6_6JYH0vMCnmnMD1c_JTrVZPSX_ohP6kEyr_5pjscjuBfaCPX18B_sjQ-KKLj6Fm4sf_2h5fF3RZEvy1PaV-ARvs0MM
startdate200903
enddate200903
creator
0Jaeger, Beate R
1Richter, Yvonne
2Nagel, Dorothea
3Heigl, Franz
4Vogt, Anja
5Roeseler, Eberhard
6Parhofer, Klaus
7Ramlow, Wolfgang
8Koch, Michael
9Utermann, Gerd
10Labarrere, Carlos A
11Seidel, Dietrich
generalNature Publishing Group
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
83V.
97X7
107XB
1188E
128FI
138FJ
148FK
15ABUWG
16BENPR
17FYUFA
18GHDGH
19K9.
20M0S
21M1P
22PQEST
23PQQKQ
24PQUKI
25PRINS
267X8
sort
creationdate200903
titleLongitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events
authorJaeger, Beate R ; Richter, Yvonne ; Nagel, Dorothea ; Heigl, Franz ; Vogt, Anja ; Roeseler, Eberhard ; Parhofer, Klaus ; Ramlow, Wolfgang ; Koch, Michael ; Utermann, Gerd ; Labarrere, Carlos A ; Seidel, Dietrich
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c405t-5a4d5123282608581f831cf8190ad67e3ec6250d98ac32aedf7c042b65452f173
rsrctypearticles
prefilterarticles
languageeng
creationdate2009
topic
0Adult
1Aged
2Antilipemic agents
3Blood Component Removal
4Blood lipoproteins
5Cohort Studies
6Combined Modality Therapy
7Coronary Artery Disease - drug therapy
8Coronary Artery Disease - prevention & control
9Coronary Artery Disease - therapy
10Coronary heart disease
11Dosage and administration
12Female
13Health aspects
14Humans
15Hypolipidemic Agents - therapeutic use
16Lipoprotein(a) - blood
17Lipoproteins
18Longitudinal Studies
19Male
20Middle Aged
21Prevention
22Proteolipids
23Risk factors
24Treatment Outcome
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Jaeger, Beate R
1Richter, Yvonne
2Nagel, Dorothea
3Heigl, Franz
4Vogt, Anja
5Roeseler, Eberhard
6Parhofer, Klaus
7Ramlow, Wolfgang
8Koch, Michael
9Utermann, Gerd
10Labarrere, Carlos A
11Seidel, Dietrich
12Group of Clinical Investigators
13for the Group of Clinical Investigators
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7ProQuest Central (Corporate)
8Health & Medical Collection
9ProQuest Central (purchase pre-March 2016)
10Medical Database (Alumni Edition)
11Hospital Premium Collection
12Hospital Premium Collection (Alumni Edition)
13ProQuest Central (Alumni) (purchase pre-March 2016)
14ProQuest Central (Alumni Edition)
15ProQuest Central
16Health Research Premium Collection
17Health Research Premium Collection (Alumni)
18ProQuest Health & Medical Complete (Alumni)
19Health & Medical Collection (Alumni Edition)
20Medical Database
21ProQuest One Academic Eastern Edition
22ProQuest One Academic
23ProQuest One Academic UKI Edition
24ProQuest Central China
25MEDLINE - Academic
jtitleNature clinical practice cardiovascular medicine
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Jaeger, Beate R
1Richter, Yvonne
2Nagel, Dorothea
3Heigl, Franz
4Vogt, Anja
5Roeseler, Eberhard
6Parhofer, Klaus
7Ramlow, Wolfgang
8Koch, Michael
9Utermann, Gerd
10Labarrere, Carlos A
11Seidel, Dietrich
aucorp
0Group of Clinical Investigators
1for the Group of Clinical Investigators
formatjournal
genrearticle
ristypeJOUR
atitleLongitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events
jtitleNature clinical practice cardiovascular medicine
addtitleNat Clin Pract Cardiovasc Med
date2009-03
risdate2009
volume6
issue3
spage229
epage239
pages229-239
issn
01743-4297
11759-5002
eissn
01743-4300
11759-5010
abstractWe investigated in a longitudinal, multicenter, cohort study whether combined lipid apheresis and lipid-lowering medication can reduce extremely high levels of lipoprotein(a) (Lp[a]) and thus prevent major adverse coronary events (MACE) more efficaciously than lipid-lowering medication alone. Eligible patients had coronary artery disease and Lp(a) levels > or =2.14 micromol/l (95th percentile). All patients received lipid-lowering medications alone until maximally tolerated doses were no longer effective, followed by combined lipid apheresis and lipid-lowering medication. The rates of the primary outcome, MACE, were recorded for both periods. A total of 120 patients were included. The mean duration of lipid-lowering therapy alone was 5.6+/-5.8 years, and that of apheresis was 5.0+/-3.6 years. Median Lp(a) concentration was reduced from 4.00 micromol/l to 1.07 micromol/l with apheresis treatment (P<0.0001); the corresponding mean annual MACE rate per patient was 1.056 versus 0.144 (P<0.0001). Lowering of Lp(a) levels by apheresis was efficacious and safe, and we recommend this therapy for patients in whom maximally tolerated doses of medication alone have failed to control coronary artery disease-associated events.
copEngland
pubNature Publishing Group
pmid19234501
doi10.1038/ncpcardio1456